{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T02:14:52Z","timestamp":1736388892116,"version":"3.32.0"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1720","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Emrosi (Journey), an oral, low-dose, biphasic-release formulation of the tetracycline antibiotic minocycline, has been approved by the FDA for once-daily treatment of inflammatory lesions of rosacea (papules and pustules) in adults. Low-dose, biphasic-release doxycycline (Oracea, and generics) has been available for years for treatment of papulopustular rosacea.<\/jats:p>","DOI":"10.58347\/tml.2025.1720b","type":"journal-article","created":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T01:33:52Z","timestamp":1736386432000},"page":"10-11","source":"Crossref","is-referenced-by-count":0,"title":["Emrosi \u2014 Low-Dose, Biphasic Oral Minocycline for Rosacea"],"prefix":"10.58347","volume":"67","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2025,1,20]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T01:33:52Z","timestamp":1736386432000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1720b"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":0,"journal-issue":{"issue":"1720","published-online":{"date-parts":[[2025,1,20]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2025.1720b","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]}}}